Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multicenter, Double-Blind, Placebo-Controlled Efficacy and Safety Study of 8 mg PEG-Uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout

Trial Profile

Randomized, Multicenter, Double-Blind, Placebo-Controlled Efficacy and Safety Study of 8 mg PEG-Uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Pegloticase (Primary)
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms GOUT-2
  • Sponsors Savient Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2019 According to an AMPEL BioSolutions media release, new data from this trial and the extension trial has been published in Arthritis Research and Therapy.
    • 31 Aug 2018 Biomarkers information updated
    • 16 Jun 2018 Results of two randomised trials (GOUT-1 and GOUT-2; n=211) assessing the factors associated with the presence of tophi in patients with chronic refractory gout, presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top